



**CollPlant**  
Biotechnologies

Pioneering  
Regenerative  
Medicine

**CollPlant Biotechnologies Ltd.**  
4 Oppenheimer Street, Weizmann Science Park  
Rehovot 7670104 Israel  
Phone: +972 (73) 2325600  
www.collplant.com

## Company Overview

CollPlant Biotechnologies (NASDAQ:CLGN) is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and the development of medical aesthetics products. CollPlant's revolutionary products, including its BioInks, are based on its proprietary recombinant human collagen (rhCollagen) which is produced in genetically engineered tobacco plants. In October 2018 CollPlant entered into a licensing deal worth \$44 million plus royalties with United Therapeutics, a \$6.5 billion company, for its BioInk technology to manufacture 3D bioprinted lungs and kidneys for transplantation. In the medical aesthetics market, CollPlant is developing 3D bioprinted breast implants for regeneration of breast tissue, and a dermal filler product line for the \$6 billion global dermal filler market. CollPlant is currently in talks for potential strategic partnerships with big pharma companies for its BioInk and medical aesthetics technologies.

### EQUITY OVERVIEW (as of 23/12/2020)

**NASDAQ: CLGN**


**Stock Price: ~ \$10.40**

**Trading Volume (average): ~ 27,000 shares**

**Market Cap: ~ \$67 M**

**Shares Outstanding: ~ 7 M**

### 3D BIOPRINTING



### MEDICAL AESTHETICS



*Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects only management's current expectations. A fuller discussion of CollPlant Biotechnologies Ltd.'s risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.*

## Investment Highlights

### True Human Collagen Produced from Genetically Engineered Tobacco

CollPlant has the only commercially viable technology currently available to mass-produce true Type I human collagen. Collagen is an essential building block of the human body, providing structural support and biological signals to connective tissues and organs, and therefore it is a crucial component for tissue regeneration. CollPlant's proprietary technology includes the introduction into tobacco plants, of 5 human genes that are essential for the synthesis of Type I collagen. These tobacco plants produce human collagen that is superior to collagen currently on the market sourced from animals and human cadavers. rhCollagen is identical to natural human collagen, therefore it does not elicit an adverse immune response in humans. Its plant origin yields a safe product with more consistent properties, making it the ideal building block for regenerative medicine. CollPlant's rhCollagen is a broadly applicable technology platform that is cost effective and enables products for medical uses with superior biological and physical properties.

### BioInks for 3D Organ Bioprinting with Top-Tier Collaboration Deals

3D bioprinting has been gaining momentum in many medicinal applications to address the need for complex scaffolds required to generate organs, organoids, tissues, and scaffolds. CollPlant's rhCollagen-based BioInks are ideal for 3D bioprinting due to their safety profile, as well as their biological and physical properties. United Therapeutics (NASDAQ:UTHR), a leader in manufactured organs, has entered a licensing agreement with CollPlant, valued at up to \$44 million plus royalties, for the use of CollPlant's BioInks in manufacturing human lungs. Recently, in September 2020, the parties announced the expansion of the collaboration with the exercise by United Therapeutics of its option to cover a second lifesaving organ, human kidneys. CollPlant has also partnered with 3D Systems (NYSE:DDD) a leader in 3D printing, to provide integrated third parties with 3D bioprinting solutions that combine 3D Systems' printers and CollPlant's BioInks. rhCollagen enables unlimited and economical access to manufactured organs around the world, with the potential to save millions of lives annually.

### Regenerative Technology for Medical Aesthetics Market

CollPlant is developing a next-generation regenerative dermal filler for the multi-billion dollar medical aesthetics market. Over 2 million dermal filler procedures were done in the U.S. in 2019, contributing to a \$6.2 billion global dermal filler market. CollPlant's dermal filler combines the advantages of rhCollagen, which promotes tissue regeneration, cell adhesion and proliferation, with hyaluronic acid, the ingredient used in about 80% of dermal fillers today. CollPlant is also developing 3D bioprinted implants for regeneration of breast tissue. Comprised of rhCollagen combined with fat cells taken from the patient, these implants are intended to promote breast tissue regeneration. The 3D bioprinted scaffold is designed to eventually degrade and be replaced by newly grown natural breast tissue free of any foreign material. CollPlant is actively pursuing collaborations with key companies in the breast implant and dermal filler space and recently supplied its first rhCollagen order into the aesthetics market.

### Commercialized Products Yield Valuable Data

CollPlant's rhCollagen based orthobiologics product VergenixSTR, and advanced wound care product VergenixFG, have received regulatory approval in the European Union and are commercialized there. Thousands of patients have been treated, producing valuable safety and efficacy data that is beneficial to CollPlant as the Company forms strategic partnerships with industry leaders in organ manufacture and medical aesthetics.